WO1999002654A1 - Isolation of bone and cartilage precursor cells - Google Patents
Isolation of bone and cartilage precursor cells Download PDFInfo
- Publication number
- WO1999002654A1 WO1999002654A1 PCT/US1998/014587 US9814587W WO9902654A1 WO 1999002654 A1 WO1999002654 A1 WO 1999002654A1 US 9814587 W US9814587 W US 9814587W WO 9902654 A1 WO9902654 A1 WO 9902654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- site
- bone
- repair
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
Definitions
- the present invention generally relates to the isolation of precursor cells and their use in bone and cartilage regeneration procedures. More particularly, the present invention is directed to a method for isolating bone/cartilage precursor cells from a variety of body tissue types by utilizing the cell surface antigen CD34, or other precursor cell surface antigens on CD34+ cells, or by utilizing other positive and negative cell selection techniques.
- Osteogenesis and chondrogenesis are highly complex biological processes having considerable medical and clinical relevance. For example, more than 1,400,000 bone grafting procedures are performed in the developed world annually. Most of these procedures are administered following joint replacement surgeries, or during trauma surgical reconstructions.
- bone marrow contains one or more populations of pluripotent cells, known as stem cells, having the capacity to differentiate into a wide variety of different cell types ofthe mesenchymal, hematopoietic, and stromal lineages.
- the process of biological differentiation which underlies the diversity of cell types exhibited by bone marrow, is the general process by which specialized, committed cell types arise from less specialized, primitive cell types. Differentiation may conveniently be thought of as a series of steps along a pathway, in which each step is occupied by a particular cell type potentially having unique genetic and phenotypic characteristics.
- a pluripotent stem cell proceeds through one or more intermediate stage cellular divisions, ending ultimately in the appearance of one or more specialized cell types, such as T lymphocytes and osteocytes.
- the uncommitted cell types which precede the fully differentiated forms, and which may or may not be true stem cells, are defined as precursor cells.
- mesenchymal stem cells MSC
- MSC mesenchymal stem cells
- MSC bone and Joint Surg, 76-A, 579-592, 1994; J Goshima, VM Goldberg, and Al Caplan, "The osteogenic potential of culture-expanded rat marrow mesenchymal cells assayed in vivo in calcium phosphate ceramic blocks" Clin. Orthop. 262, 298-311, 1991; H Nakahara et al. "In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells” Exper. Cell Res. 195, 492-503, 1991.) Studies of this type have conclusively shown that MSC are a population of cells having the capacity to differentiate into a variety of different cell types including cartilage, bone, tendon, ligament, and other connective tissue types.
- HSC Hematopoietic stem cells
- SSC stromal stem cells
- CD34+ cells are a mixture of immature blastic cells and a small percentage of mature, lineage-committed cells ofthe myeloid, erythroid and lymphoid series. Perhaps 1% of CD34+ cells are true HSC with the remaining number being committed to a particular lineage. Results in humans have demonstrated that CD34+ cells isolated from peripheral blood or marrow can reconstitute the entire hematopoietic system for a lifetime. Therefore, CD34 is a marker for HSC and hematopoietic progenitor cells.
- CD34 is widely recognized as a marker for hematopoietic cell types, it has heretofore never been recognized as a reliable marker for precursor cells having osteogenic potential in vivo.
- the prior art has taught that bone precursor cells are not hematopoietic in origin and that bone precursor cells do not express the hematopoietic cell surface antigen CD34 (MW Long, JL Williams, and KG Mann “Expression of bone-related proteins in the human hematopoietic microenvironment" J. Clin. Invest. 86, 1387-1395, 1990; MW Long et al. "Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors" J. Clin. Invest. 95, 881-887,1995; SE Haynesworth et al. "Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies Bone, 13, 69-80, 1992).
- Caplan et al. disclose a method for isolating and amplifying mesenchymal stem cells (MSC) from marrow.
- MSC mesenchymal stem cells
- the Caplan method involves two basic steps: 1) harvesting marrow and 2) amplifying the MSC contained in the harvested marrow by a 2 to 3 week period of in vitro culturing. This method takes advantage ofthe fact that a particular culture medium favors the attachment and propagation of MSC over other cell types.
- MSC are first selected from bone marrow using specific antibodies against MSC prior to in vitro culturing.
- the in vitro amplified, marrow-isolated MSC may then be introduced into a recipient at a transplantation repair site.
- A. Caplan. "precursor cells” J. Ortho. Res. 9, 641, 1991; S.E. Haynesworth, M.A. Baber, and A.L. Caplan. "Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies," Bone, 13, 69-80, 1992.
- the current methods used to isolate precursor cells have a number of drawbacks to consider.
- Harvesting bone marrow requires an additional surgical procedure with the appendant possibility of complications from anesthesia, hemorrhage, infection, and post-operative pain.
- Harvesting periosteum or perichondrium is even more invasive.
- Second, the Caplan method requires a substantial period of time (2 to 3 weeks) for in vitro culturing of marrow-harvested MSC before the cells can be used in further applications. This additional cell culturing step renders the method time-consuming, costly, and subject to more chance for human error.
- the present invention is directed to a method for isolating precursor cells from a variety of hematopoietic and non-hematopoietic tissues wherein the precursor cells have osteogenic and chondrogenic potential.
- the precursor cells are isolated from peripheral blood, marrow, or adipose tissue based on binding by a reagent to cell surface antigen CD34 or other surface antigens on CD34+ cells.
- a method for isolating bone or cartilage precursor cells from adipose tissue is described that utilizes sedimentation density differences in the cells comprising the adipose tissue.
- the present invention also provides a method for in vivo bone and cartilage regeneration involving transplantation with CD34+ precursor cells isolated from peripheral blood, marrow, or adipose tissue.
- a direct, single- step method for in vivo bone or cartilage regeneration is provided that involves the isolation of CD34+ precursor cells from peripheral blood, marrow, or adipose tissue and immediate implantation (i.e., in the absence of an in vitro cell culturing step) at a connective tissue site needing repair.
- the present invention describes an improved bone implantation prosthetic device in which the device is seeded with precursor cells having osteogenic potential isolated from a patient's peripheral blood, bone marrow, or adipose tissue.
- the ability to isolate autologous precursor cells having osteogenic and chondrogenic potential has far reaching clinical implications for bone and cartilage repair therapies, either alone or in conjunction with prosthetic devices.
- the present invention provides a simple method for isolating precursor cells having the potential to generate bone or cartilage from a variety of tissue types including peripheral blood, marrow, and adipose tissue.
- the precursor cells can be isolated using reagents that recognize CD34 or other markers on the surface of CD34+ precursor cells, for example CD33, CD38, CD74, and THY1.
- precursor cells or precursor cell enriched cell populations can be isolated by negative selection techniques adapted to separate precursor sells from non-precursor cells.
- a cell population enriched in precursor cells can be separated using sedimentation/density differential based techniques.
- the present invention does not require in vitro culturing of isolated precursor cells before the cells are used in in vivo applications. Indeed, precursor cells isolated by the present invention may be transplanted in vivo immediately for bone or cartilage regeneration. Thus, the 2 to 3 week time delay required by other methods for in vitro culturing of progenitor cells is eliminated making the method economical, practical and useful for the clinical environment.
- the present invention relates to a method for isolating precursor cells having the potential to generate bone or cartilage directly from hematopoietic and non-hematopoietic tissues, including peripheral blood.
- the method includes the steps of collecting tissue samples, contacting the sample with an antibody or other reagent that recognizes antigen CD34, or other antigens on CD34+ precursor cells, and separating the reagent-precursor cell complex from unbound material, by for example, affinity chromatography.
- Precursor cells isolated by the present method may be used immediately for bone and cartilage regeneration in vivo.
- the present invention is a method for isolating precursor cells from peripheral blood, marrow or adipose tissue wherein the precursor cells have the potential to generate bone or cartilage.
- the present invention is directed to a method for isolating osteogenic and/or chondrogenic precursor cells based on selecting cells from hematopoietic and non-hematopoietic tissues that carry cell surface marker CD34.
- the present invention is directed to a method for bone or cartilage regeneration which utilizes CD34+ precursor cells isolated from peripheral blood, marrow, or adipose tissue.
- Adipose tissue is one ofthe most convenient sources of precursor cells in the body.
- the term "adipose tissue” is intended to mean fat and other sources of microvascular tissue in the body such as placenta or muscle. The term specifically excludes connective tissues, hematologic tissues, periosteum, and perichondrium.
- the capacity to promote cartilage growth is applied to cells which stimulate cartilage growth, such as chondrocytes, and to cells which themselves differentiate into chondrocytes.
- the term also applies to certain bioactive compounds, such as TGF- ⁇ , which promote cartilage growth.
- the pathway to terminal differentiation ends with a highly specialized cell having unique genetic and phenotypic characteristics.
- Primitive cell having the capacity to self-renew and to differentiate into all blood cell types.
- Mesenchymal Stem Cell Primitive cell type having the capacity for self-regeneration and for differentiation through a series of separate lineages to produce progeny cells having a wide variety of different phenotypes, including bone, cartilage, tendon, ligament, marrow stroma, adipocytes, dermis, muscle, and connective tissue.
- Microvascular Cell Cells comprising the structure ofthe microvasculature such as endothelial, smooth muscle, and pericytes.
- the capacity to promote or to generate the production of bone may be applied to osteoblasts which have the capacity to promote bone growth, or to cells which themselves are able to differentiate into osteoblasts. The term would also apply to growth factors having the capacity to promote bone growth.
- a cell with the potential to differentiate to perform a specific function A cell with the potential to differentiate to perform a specific function.
- Stem Cell Pluripotent precursor cell having the ability to self-renew and to generate a variety of differentiated cell types.
- the present invention is premised upon two surprising discoveries. First, that precursor cells, having the potential to form connective tissue in vivo, can be isolated from a variety of hematopoietic and non-hematopoietic tissue sources, including peripheral blood and adipose tissue. And second, that the cell surface marker CD34, a heretofore unrecognized identifier for connective tissue precursor cells, may be used as a marker for precursor cells having the potential to form bone and cartilage in vivo.
- CD34 a heretofore unrecognized identifier for connective tissue precursor cells
- the inventors have discovered two convenient, new sources for osteogenic and chondrogenic precursor cells (viz. peripheral blood and adipose tissue), and a population of cells isolated from marrow which do not require an in vitro culture step before implantation into the host to induce repair of bone or cartilage.
- the present invention enables isolation of these cells from more conveniently harvested tissues, such as peripheral blood and adipose tissue.
- the ability to isolate osteogenic and chondrogenic precursor cells from tissues other than marrow and periosteum lends considerable convenience and simplicity to an otherwise complicated method.
- the present invention is an affinity method enabling the isolation of precursor cells in humans having the potential to generate connective tissue based on expression of antigen CD34 and other cell surface markers on CD34+ cells.
- Some examples of other markers on CD34+ cells would include CD33, CD38, CD74, and THY1, which list is not intended to be exclusive.
- precursor cells are isolated from adipose tissue based on differential sedimentation properties.
- adipose tissue can be dissociated into a suspension of cells, and the fat cells can be separated from precursor cells based on the higher density ofthe precursor cells (i.e., greater than 1.0 g/cm 3 ) relative to the density of fat cells (i.e., less than or equal to 1.0 g/cm 3 ) and other undesirable cells and cell components.
- the present invention enables the immediate use of isolated precursor cells for bone and cartilage regeneration procedures without the need for in vitro culturing. As a consequence, the present method is quicker and easier to implement than previously described procedures. 1. Isolating Precursor Cells
- the present method for isolating precursor cells involves collecting a body tissue sample, contacting the sample with an antibody or other reagent that recognizes and binds to an antigen on the surface ofthe precursor cells, and then separating the precursor cell-reagent complex from unbound material by, for example, affinity chromatography.
- the method can be applied to peripheral blood, marrow, or other tissues, including adipose tissue. For ease and simplicity of isolation, however, blood is the preferred source material since surgical procedures are not required. (a) Peripheral blood as the source of precursor cells
- Red blood cells may be removed from the sample by any suitable means, for example, lysis, centrifugation, or density gradient separation. It is preferred that the sample also be anticoagulated by, for example, treatment with citrate, heparin, or EDTA.
- the yield of precursor cells is expected to be about 0.1 % to 0.5% of the population of nucleated blood cells. Yields may vary, depending upon the health and age ofthe donor, and on the freshness ofthe sample. The yield may be dramatically increased by administering drugs or growth factors to the patient before blood collection. Although the method will work on samples which have been stored under refrigeration, fresh samples are preferred.
- a critical step in a positive selection procedure for isolating precursor cells from peripheral blood involves contacting the blood sample with a reagent that recognizes and binds to a cell surface marker on CD34+ cells. Any reagent which recognizes and binds to CD34+ cells is within the scope ofthe invention.
- Suitable reagents include lectins, for example, soy bean agglutinin (SBA), and L-selectin.
- the sample is contacted with an antibody against CD34.
- Either monoclonal (mAb) or polyclonal antibodies may be used.
- Methods for preparing antibodies directed against CD34 and other cell surface antigens on CD34+ cells are well known to those skilled in the art.
- Suitable human antibody preparations directed against CD34 and other cell surface markers on CD34+ cells may be obtained commercially from Cell Pro, Inc., Bothell, WA, or Becton- Dickinson, Mountain View, CA.
- Suitable cell surface antigens on precursor cells include CD34 and other antigens on CD34+ cells, for example THY1, CD33, CD38, and CD74.
- the preferred cell surface marker is CD34. It is expected that the procedure will be successful using other cell surface antigens on CD34+ cells as markers for precursor cells.
- the precursor cell-antibody complex is recovered by any suitable method such as, for example, affinity chromatography, magnetic beads, and panning.
- recovery is by affinity chromatography.
- affinity chromatography See, e.g., RJ Berenson et al. "Positive selection of viable cell populations using avidin-biotin immunoadsorption” J. Immunolog. Meth. 91, 11-19, 1986.
- the affinity recovery method in accordance with one embodiment utilizes a biotin-avidin coupling reaction in which the antibody is coupled to biotin by any suitable method.
- the antibody-biotin labeled precursor cell complex is separated from unbound materials by passing the reaction mixture through a column packed with an avidin labeled matrix. Unbound materials are removed from the column by washing.
- a useful commercially available cell separation kit includes biotin- labeled human anti-CD34 and a column packed with an avidin labeled matrix ("CEPRATE®LC” available from CellPro, Inc. Bothell, WA).
- the primary antibody could be directed against a precursor cell surface marker and a secondary antibody, labeled with biotin, directed against the primary antibody.
- the secondary antibody may be coupled to a suitable solid support material.
- Negative selection schemes are also intended to be within the scope of the invention.
- the antibody, or other reagent would be directed against a cell surface marker which is absent on CD34+ cells.
- the cells failing to bind to the reagent i.e., antibody or lectin
- a cell population enriched for cells having osteogenic and chondrogenic potential is prepared by contacting cells isolated from peripheral blood, bone marrow or adipose tissue with a reagent composition that binds to surface antigens not present on the surface of cartilage and bone precursor cells.
- enriched cell population is used in accordance with the present invention to designate a population of cells that have a higher percentage of a particular cell type relative to the percentage of that cell type in the natural tissue from which the cells were isolated.
- the reagent composition can be selected from lectins or antibodies that bind to cell surface antigens selected from the group consisting of CD3, CD8, CD10, CD15, CD19 and CD20.
- the CD3 and CD8 antigens are associated with T cells
- the CD 19 and CD20 antigens are associated with B cells
- the CD 15 antigen is associated with granulocytes
- the CD 10 antigen is associated with lymphoid precursors and granulocytes.
- a combination of antibodies is utilized to bind several different antigens that are present on non progenitor cells.
- the cells not binding to the reagent composition are then recovered.
- Standard separation techniques including chromatography, magnetic beads or panning, can be utilized to separate the cells that bind to the reagent from the cells that do not bind the reagent.
- Bone marrow is collected by any suitable fashion, for example iliac crest aspiration.
- the marrow is treated with an anticoagulant such as EDTA, heparin, or citrate and nucleated cells are separated from non-nucleated cells by any suitable means, for example by hemolysis or by density gradient centrifugation.
- Precursor cells that express the CD34 cell surface antigen are isolated from marrow using a reagent that recognizes and binds to CD34 or to some other antigen on the surface of CD34+ cells. Suitable reagents include antibodies, lectins, and attachment molecules.
- Bound cells are separated from unbound cells by affinity chromatography, magnetic beads, or by panning.
- an antibody directed against CD34 is used in the binding reaction and bound cells are separated from unbound cells by affinity chromatography, as disclosed more fully in the examples which follow.
- adipose tissue is used throughout this disclosure in a generic sense to mean fat and other tissue types (excluding connective tissues, hematologic tissues, periosteum, and perichondrium) which contain microvascular cells.
- Microvascular tissue from which capillaries are made, is an integral part ofthe blood transport system and, as such, is ubiquitous throughout the body. Microvascular tissue is composed of at least three cell types - endothelial, pericytes, and smooth muscle. Early investigations suggested that microvascular tissue might play an important role in bone metabolism. A key observation was that microvascular cells and tissue arose de novo and proliferated at sites of bone repair and new bone growth.
- endothelial cells, pericytes, or both may be osteoprecursor cells, or alternatively, that microvascular cells exert a mitogenic effect on bone precursor cells.
- endothelial cells, pericytes, or both may be osteoprecursor cells, or alternatively, that microvascular cells exert a mitogenic effect on bone precursor cells.
- the method ofthe present invention as applied to adipose tissue, has two embodiments.
- the tissue is contacted with a reagent that recognizes CD34 or another surface antigen on CD34+ cells.
- suitable binding reagents for use with adipose tissue include lectins, antibodies, and attachment molecules.
- the affinity binding method, as applied to adipose tissue differs from the method as applied to blood and marrow by the requirement of an additional step of producing a single-cell suspension before incubation with the antigen binding reagent. Any suitable dissociation enzyme such as, for example, collagenase may be used.
- Cells that bind the reagent can be removed from unbound cells by any suitable means, for example affinity chromatography, magnetic beads, or panning.
- a sedimentation method is utilized to obtain a fraction of cells that is enriched for precursor cells having osteogenic and chondrogenic potential.
- the cells are separated by gravity sedimentation on the bench top, or by centrifugation.
- fat could be secured by liposuction or any other suitable method.
- About 10 cc to 30 cc of fat tissue is digested with enough dissociation enzyme (e.g., collagenase) to produce a single-cell suspension.
- Suitable reaction conditions for enzyme digestion will vary depending on the enzyme used, as known to those skilled in the art.
- the adipocytes are separated from other cell types by centrifugation.
- the cells are suspended in a buffered aqueous solution, wherein adipocytes float to the surface while denser cells having a density greater than 1.0 g/cm 3 , which include precursor cells, collect on the bottom and are separable thereafter by any suitable means.
- After washing the harvested precursor cells they can be mixed with a suitable carrier and immediately implanted in vivo at a site needing repair.
- the precursor cells recovered by the present procedure are useful for a variety of clinical applications. For example, they may be transplanted without further processing to a connective tissue site in a patient to promote the repair or regeneration of damaged bone or cartilage.
- the present invention does not require in vitro culturing in order to obtain a suitable cell type or an adequate quantity of precursor cells to be of use for in vivo application.
- the present invention takes advantage ofthe unexpected finding that osteogenic and chondrogenic precursor cells may be isolated from a variety of hematopoietic and non-hematopoietic body tissues such as peripheral blood and adipose tissue. This finding has created a heretofore unappreciated reservoir of precursor cells that can be drawn from conveniently to provide enough cells for in vivo applications without an additional time-consuming step of amplifying cell numbers by in vitro culturing. This aspect ofthe invention saves time and money with less risk of complication and pain for the patient.
- the precursor cells isolated by the present method from any suitable tissue source may be implanted at any connective tissue site needing bone or cartilage regeneration. Suitable implanting procedures include surgery or arthroscopic injection. While the factors that determine biological differentiation are not fully understood, it is known that precursor cells will differentiate into bone or cartilage if transplanted to a site in the body needing repair. Precursor cells isolated by the present method can be implanted alone or premixed with bioactive compounds, for example, cell signaling molecules, including growth factors.
- Bioactive compounds suitable for use in accordance with the present invention include: transforming growth factor beta (TGF ⁇ ), bone morphogenic protein 2, 3, 4, or 7 (BMP 2, 3, 4, 7), basic fibroblast growth factor (bFGF), insulin-like growth factor I (IGF-I), sonic hedgehog (shh), indian hedgehog (ihh), growth and differentiation factors 5, 6, or 7 (GDF 5, 6, 7).
- TGF ⁇ transforming growth factor beta
- BMP 2 basic fibroblast growth factor
- IGF-I insulin-like growth factor I
- shh sonic hedgehog
- ihh indian hedgehog
- growth and differentiation factors 5, 6, or 7 GDF 5, 6, 7
- Other cell signaling molecules suitable for use in accordance with the present invention include: vitronectin (VN), laminin (LN), bone sialoprotein (BSP), and osteopontin (OPN).
- a method for inducing the production of cartilage or bone at a predetermined site in need of repair.
- the method comprises the step of contacting the site with a composition comprising a population of cells enriched for cells having osteogenic and chondrogenic potential, wherein the cells are isolated from peripheral blood, bone marrow or adipose tissue.
- the population of cells is enriched in progenitor cells wherein the enriched population of cells is prepared based on the failure of progenitor cells to bind a reagent specific for a cell surface antigen selected from the group consisting of CD3, CD8, CD10, CD15, CD19 and CD20.
- the enriched population of cells is prepared by contacting a cell suspension prepared from peripheral blood, bone marrow or adipose tissue with a reagent that binds to cells bearing the CD34 antigen, to form a mixture of reagent bound cells and cells not bound to the reagent, and separating the reagent bound cells from the unbound cells using standard chromatography, magnetic beads or panning techniques.
- the cartilage or bone progenitor cells are combined with a biocompatible carrier material, well known to those skilled in the art, before the cells are surgically implanted or injected into a patient.
- the carrier functions to impede the dislodgement ofthe implanted cells and may also serve to further enhance the repair ofthe damaged or diseased tissue.
- Suitable carriers include but are not limited to, proteins such as collagen, gelatin, fibrin fibrin clots, demineralized bone matrix (DBM), Matrigel® and Collastat®; carbohydrates such as starch, polysaccharides, saccharides, amylopectin, Hetastarch, alginate, methylcellulose and carboxymethylcellulose; proteoglycans, such as hyaluronate; agar; synthetic polymers; including polyesters (especially of normal metabolites such as glycolic acid, lactic acid, caprolactone, maleic acid, and glycols), polyethylene glycol, polyhydroxyethylmethacrylate, polymethylmethacrylate, poly(amino acids), polydioxanone, and polyanhydrides; ceramics, such as tricalcium phosphate, hydroxyapatite, alumina, zirconia, bone mineral and gypsum; glasses such as Bioglass, A-W glass, and calcium phosphate glasses; metals including titanium, Ti-6
- a variety of clinically useful prosthetic devices have been developed for use in bone and cartilage grafting procedures. (See e.g., Bone Grafts and Bone Substitutions. Ed. M.B.Habal & A.H. Reddi, W.B. Saunders Co., 1992.)
- effective knee and hip replacement devices have been and continue to be widely used in the clinical environment.
- Many of these devices are fabricated using a variety of inorganic materials having low immunogenic activity, which safely function in the body. Examples of synthetic materials which have been tried and proven include titanium alloys, calcium phosphate, ceramic hydroxyapatite, and a variety of stainless steel and cobalt-chrome alloys.
- These materials provide structural support and can form a scaffolding into which host vascularization and cell migration can occur.
- surface-textured prosthetic devices are effectively anchored into a host as bare inorganic structures, their attachment may be improved by seeding with osteogenic precursor cells, or bioactive compounds which attract and activate bone forming cells. Such "biological-seeding" is thought to enhance the effectiveness and speed with which attachment occurs by providing a fertile environment into which host vascularization and cell migration can occur.
- the present invention provides a source of precursor cells which may be used to "seed" such prosthetic devices.
- precursor cells are first mixed with a carrier material before application to a device.
- Suitable carriers well known to those skilled in the art include, but are not limited to, gelatin, fibrin, collagen, starch, polysaccharides, saccharides, proteoglycans, synthetic polymers, calcium phosphate, or ceramics. The carrier insures that the cells are retained on the porous surface ofthe implant device for a useful time period.
- kits useful for preparing prosthetic devices for bone and cartilage grafting procedures includes the one or more of a selection of biocompatible carriers and a reagent composition for preparing a population of cells enriched in progenitor cells from patient tissue.
- the kit comprises an enzyme mixture for producing a cell suspension from adipose tissue and a carrier matrix for combination with a population of cells enriched in progenitor cells derived from said cell suspension.
- the kit can also include buffers for use with the enzyme mixture and buffers for washing and handling the cell suspension.
- the kit can include disposable attachments for liposuction devices and disposable vessels for handling the isolated adipose tissue and cell suspension.
- the kit can also include a reagent composition that binds to cells bearing the CD34 antigen or a reagent composition that includes components binds to cells bearing an antigen selected from the group consisting of CD3, CD8, CD10, CD15, CD19 and CD20.
- a rat calvarial model was used to test the operability ofthe invention for in vivo applications.
- the model consisted of monitoring the ability of various test samples to promote bone growth in calvarial defects which had been surgically introduced into the rat skull.
- Calvarial defects were introduced into 6 month to 9 month old Fisher rats having bodyweights in the range of about 300 g to 500 g according to the following procedure.
- Animals were anesthetized by intramuscular injection using a KetamineRompun (xylazine)- Acepromazine (acepromazine maleate) cocktail, and surgical incisions made in the calvarial portion ofthe skull.
- a circular portion ofthe skull measuring 8 mm in diameter was removed using a drill with a circular trephine and saline irrigation.
- An 8 mm diameter disk of "GELFLLM” was placed in each defect to separate the exposed brain from the test material and to maintain hemostasis.
- the calvarial defects produced in this fashion were then packed with a test sample consisting of an isolated cell population.
- the test samples were mixed with a carrier material consisting of rat tail collagen or Avitene® bovine collagen before introduction into the calvarial defect.
- the positive control consisted of an autograft while the negative control consisted of a tricalcium phosphate (TCP) carrier only implant.
- Defect 0 No net gain in bone; either less formation than resorption or no formation at all. 1 Less that 5% of linear distance between cut bone edges is bridged by new bone. 2 About 5% to 33% ofthe defect is bridged by new bone, or there is an island of bone in the central portion ofthe defect. 3 About 33% to 66% ofthe defect is bridged by new bone. 4 Greater than 66% ofthe defect is bridged by new bone. 5 Complete bridging ofthe defect by new bone.
- RBRA Relative bone regeneration activity
- N Number of experiments
- S.D. Standard deviation 2C6 and 5E6 cells were isolated from marrow
- SBA Soy Bean Agglutinin EXAMPLE 2
- Rat bone marrow was isolated from the intramedullary cavities of 6 femurs taken from male Fisher rats between 8 to 10 weeks of age. Prior to sacrifice the animals had been maintained on a normal food and water diet. The marrow was extracted from excised femurs by flushing into a test tube containing approximately 5 ml of ACD buffer. Buffer ACD in the neat state consists of 2.2g Na 3 Citrate.2H 2 O, 0.8g citric acid, and 2.4g dextrose dissolved in 100 ml distilled water. Unless otherwise noted, buffer ACD was diluted to a concentration of 15% in PBS. The extracted marrow cells were gently suspended into the buffer solution by pipetting.
- the marrow cell suspension was underlaid with approximately 4 ml of Ficoll-Hypaque with a specific gravity of 1.09 (Sigma Chemical Co., St. Louis, MO) and centrifuged at 1200 x g for 20 minutes. After centrifugation the interface layer containing the nucleated cells was removed by pipetting. The cells were washed in 5 ml of ACD and centrifuged at 250 x g for 6 to 7 minutes. The pellet was washed twice more in 1% BSA/PBS (bovine serum albumin, phosphate buffered saline; supplied with CEPRATE LC kit). All PBS was Ca +2 and Mg +2 free to prevent clotting.
- BSA/PBS bovine serum albumin, phosphate buffered saline
- Mouse IgM monoclonal antibodies 2C6 and 5E6 were raised against rat
- CD34 present on the surface of a subpopulation of rat hematopoietic cells.
- the CD34 mAb's used in these experiments were the gift of Dr. Othmar Forster and were prepared in a manner well-known to those skilled in the art.
- Anti-mouse IgM:FITC used for fluorescence sorting of cells bound with mAb's 2C6 and 5E6, was obtained from Boehringer Mannheim, Cat. #100807.
- Avidin:FITC also used in fluorescence sorting was obtained from Boehringer Mannheim, Cat. #100205.
- CD34+ cells labeled with mAb 2C6 or 5E6 were separated from unbound cells using an affinity column method.
- a useful, commercially available affinity cell separation kit, "CEPRATE LC,” may be obtained from CellPro (CellPro, Inc. Bothell, WA 98021). Anti-mouse IgM:biotin was purchased from Southern Biotech, Birmingham, AL, Cat. #1022-08.
- Cells carrying the CD34 surface antigen were isolated from rat marrow as follows. The rinsed nucleated cells, isolated in the manner described in Example 2, were resuspended in about 0.5 ml of 1%BSA/PBS (from CellPro kit). Then, a volume of mAb ranging in concentration from about 1 ⁇ g/ml to 40 ⁇ g/ml was added and the mixture incubated for about one hour at room temperature with occasional, gentle agitation.
- the mixture was brought to 10 ml with 1% BSA/PBS and the mixture centrifuged at 250 x g for six minutes. The pellet was gently resuspended and rinsed two additional times in 10 ml 1%BSA/PBS and spun as before. After another resuspension and centrifugation, the final cell pellet was resuspended in 2 ml 1% BSA/PBS for incubation with a biotinylated anti-mouse IgM.
- Antibody-labeled and unlabeled cells were separated on the "CEPRATE LC" avidin column using the conditions recommended by the manufacturer (Cell Pro, Inc., Bothell, WA). Briefly, the column contained a bed of PBS- equilibrated avidin matrix. Prior to loading the sample, about 5 ml of 5% BSA was run through the column. The pre-diluted cell sample was then layered onto the top ofthe gel matrix and the sample thereafter allowed to run into the matrix gel. Unlabeled cells were washed from the column with about 3 ml to 5 ml of PBS.
- the mAb-labeled cells were then released from the matrix and collected into a small volume of 5% BSA by gently squeezing the column so as to agitate the matrix while washing the column with PBS. Small aliquots were saved from the bound and unbound fractions for cell counting and flow cytometry. For implantation experiments the cells were washed 2 times in PBS/BSA and once in PBS only. Results.
- Each experiment generated about 10 to 20 x 10 6 adherent cells of which about half this number were implanted into a calvarial defect.
- Cell fractions taken from the column were tested for viability by trypan blue cell counts using a hemacytometer and found to be in the range of about 85% to 97% viable.
- the adherent cell population appeared to be a group of small blast cells.
- FACS was used to determine the purity of CD34+ cells isolated on the column.
- the adherent cell population contained about 50% ofthe original number of CD34+ cells at a purity of about 50%.
- CD34+ cells were implanted into rat calvarial defects with or without a suitable carrier material. Two carriers were tried in these experiments, Avitene bovine collagen and rat tail collagen, both of which were found to be useful.
- Rat tail collagen is preferred, however, since it showed the least inflammatory response.
- About 50 mg of collagen was dissolved in 1 ml of PBS at 60 °C and equilibrated to 37 °C prior to mixing with cells.
- pellets containing collagen and cells were formed by mixing 100 ⁇ l of collagen solution with a cell pellet and cooling the mixture to 4°C prior to implantation into a calvarial defect. Surgical implantations were performed as described in Example 1 with sacrifice of recipient animals at 28 days post-surgery.
- ACD Stock Solution ACD Working Solution 2.2 g Na 3 Citrate.2H 2 0 15 ml ACD Stock Solution
- Blood was placed into 15 ml conical tubes and brought up to 5 ml with ACD working solution.
- the samples were underlaid with 4 ml of Ficoll-Hypaque and centrifuged at 1200 xg at room temperature for 20 minutes. After centrifugation, the white cell layer was removed from each tube by pipet.
- Ficoll-separated blood cells were used for implantation experiments, either directly or after mixing with a carrier material.
- the cell pellet was washed twice in 10 ml of PBS and the final pellet, containing roughly 5 to 10 x 10 6 cells, delivered neat into a calvarial defect.
- Cell samples pre-mixed with a carrier material were combined with rat tail collagen prior to implantation.
- About 50 mg of rat tail collagen obtained from Sigma, St. Louis, MO; Cat.# C-8897
- the collagen solution was equilibrated to 37°C prior to mixing with the cell pellet.
- About 60 ⁇ l of collagen solution was mixed with the cell pellet and the entire cell-collagen mixture implanted into a calvarial defect.
- Hemolysis Buffer - IPX Stock Solution Dissolve the following in 1 L distilled water, adjust pH to 7.3, filter sterilize and store at 2 - 8°C. 83 g NH 4 C1 lO g NaHCO, 4 g Na.EDTA (2) Phosphate Buffered Saline (PBS ⁇ l Ca2+ and Me2+ Free
- step (b) The cell pellet, resuspended in 2 ml PBS BSA as in step (a), was incubated with 3 ml of neat mAb 2C6 in order to bind CD34+ cells.
- the mAb-cell mixture was incubated at 4°C for 45 minutes and the cells gently agitated once to resuspend during incubation. Following the incubation period the volume was brought up to 10 ml with PBS/BSA and the sample washed twice as in step (a).
- the washed pellet was resuspended in 2 ml PBS/BSA and 15 ⁇ l of goat anti-mouse IgM:biotin was added for a 30 minute incubation at 4°C with one gentle agitation during incubation to resuspend cells.
- the cells were rinsed twice in PBS/BSA, as described in step (a), and the final pellet resuspended in 10 ml of 5% BSA. 5 ml ofthe resuspended pellet were used for each of two "CEPRATE LC" column sorts, as described in Example 3.
- Antibody-bound cells were released from the column as described in Example 3 and the released cells washed twice in PBS/BSA, and once in PBS.
- the final cell pellet was mixed on a glass slide with 60 ⁇ l of rat tail collagen (100 mg/ml) at 37 °C, and the mixture of collagen and cells placed briefly on ice to form a solid pellet. The cell containing pellet was then transplanted immediately into a rat calvarial defect, as described in Example 1.
- Two epididymal fat pads were removed by dissection from a male Fisher F344 rat, minced with scissors under sterile conditions, and incubated in 10 ml PBS/1%BSA in the presence of 8 mg/ml collagenase (Type II Crude, 273U/mg; Worthington Laboratories) for 45 minutes at 37° C with gentle shaking. After digestion the sample was centrifuged at 250 xg for 4 minutes and the low density fat at the top ofthe tube removed by aspiration. The pellet, which contained the precursor cells, was washed twice in PBS/1%BSA and once in PBS. The washed pellet was mixed with 50 ⁇ l rat tail collagen at 37°C, placed briefly on ice to gel, and implanted into a rat calvarial defect.
- Endothelial cell growth supplement ECGS + Heparin (100X stock): Endothelial cell growth supplement (Sigma Cat # E-2759) 3.0 mg/ml in PBS Heparin (Sigma Cat. # H3149) 10,000 units/ml in PBS
- Chill reagents and combine on ice. Quickly introduce 3 -4ml of mixture into each T-25 flask or 35mm petri dish and harden to a gel at 37°C for 30 min. before plating cells. Cells were grown on both substrates in each ofthe three culture media formulations with three media changes per week. B-glycerophosphate was added to some cultures beginning at different time points and continued through the duration of the experiments.
- DBM Demineralized bone matrix
- hemostatic microfibrillar collagen (Collastat® OBP, Vitaphore Corporation) was combined with the final cell pellet in a small volume of PBS and gently kneaded into a putty-like material prior to implantation.
- RBRA with this treatment was 2.67 +/- 0.49
- Sodium hyaluronate gel (Orthovisc®, Anika Research, Inc.) was dispensed dropwise from the sterile packaging syringe onto the washed cell pellet and gently mixed with the cells.
- the approximate amount of hyaluronan per calvarial defect was 60-70 ⁇ l.
- a mechanical method was used to produce fibrin clots directly from whole blood.
- 5 ml of blood was obtained from a donor Fisher (F344) rat via cardiac stick and placed immediately into a sterile tube.
- the blood was manually stirred in a circular motion with a roughened glass rod for 1-2 minutes until a clot formed around the rod.
- the rod was then touched to the side ofthe tube, twisted to remove excess blood cells and the final clot was gently slipped off and stored between sterile moistened gauze until transplantation.
- the resultant clot was a hollow 20-25mm cylinder.
- Precursor cell pellets were pipetted directly into the center ofthe cylinder and each clot was used to fill two calvarial defects.
- RBRA with this treatment was 1.83 +/-
- Microvascular endothelial cells isolated from fat were isolated as described in Example 6. Rat tail collagen was prepared and held at 37°C.
- vitronectin (murine) (Gibco Cat. # 12174-017) was added directly into the rat tail collagen to a resulting concentration of 10 ⁇ g/ml.
- 60 ⁇ l ofthe RTC/vitronectin mixture was mixed with each cell pellet, chilled briefly on ice to harden, then transplanted into the calvarial defect resulting in a final concentration of 600ng of vitronectin per implant.
- the concentration of vitronectin was the most useful of several doses tried.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98934544A EP1007632A4 (en) | 1997-07-14 | 1998-07-14 | Isolation of bone and cartilage precursor cells |
JP2000502153A JP2003517259A (en) | 1997-07-14 | 1998-07-14 | Method for isolating bone and precursor chondrocytes |
AU84040/98A AU756411B2 (en) | 1997-07-14 | 1998-07-14 | Isolation of bone and cartilage precursor cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/891,952 | 1997-07-14 | ||
US08/891,952 US6200606B1 (en) | 1996-01-16 | 1997-07-14 | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999002654A1 true WO1999002654A1 (en) | 1999-01-21 |
Family
ID=25399106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/014587 WO1999002654A1 (en) | 1997-07-14 | 1998-07-14 | Isolation of bone and cartilage precursor cells |
Country Status (5)
Country | Link |
---|---|
US (1) | US6200606B1 (en) |
EP (1) | EP1007632A4 (en) |
JP (1) | JP2003517259A (en) |
AU (1) | AU756411B2 (en) |
WO (1) | WO1999002654A1 (en) |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001080865A2 (en) * | 2000-04-25 | 2001-11-01 | Osiris Therapeutics, Inc. | Joint repair using mesenchymal stem cells |
WO2002055678A1 (en) * | 2001-01-10 | 2002-07-18 | Centre National De La Recherche Scientifique-Cnrs | Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues |
JP2002537849A (en) * | 1999-03-10 | 2002-11-12 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | Fat-derived stem cells and lattice |
EP1434855A2 (en) * | 2001-09-10 | 2004-07-07 | The Regents of the University of California | Adipose-derived stem cells and lattices |
US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
AU2006200478B2 (en) * | 2000-04-25 | 2007-08-02 | Mesoblast International Sarl | Joint repair using mesenchymal stem cells |
WO2007127436A2 (en) * | 2006-04-27 | 2007-11-08 | Rhode Island Hospital | Methods and compositions for repairing cartilage |
EP1915109A2 (en) * | 2005-08-01 | 2008-04-30 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Use of adipose tissue-derived stromal cells in spinal fusion |
US7390484B2 (en) | 2001-12-07 | 2008-06-24 | Cytori Therapeutics, Inc. | Self-contained adipose derived stem cell processing unit |
US7531355B2 (en) | 2005-07-29 | 2009-05-12 | The Regents Of The University Of California | Methods and compositions for smooth muscle reconstruction |
US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US7595043B2 (en) | 2001-12-07 | 2009-09-29 | Cytori Therapeutics, Inc. | Method for processing and using adipose-derived stem cells |
US7651684B2 (en) | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
US7863043B2 (en) | 2004-02-11 | 2011-01-04 | Aldagen, Inc. | Stem cell populations and methods of use |
USRE43282E1 (en) | 1998-09-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US8691216B2 (en) | 2001-12-07 | 2014-04-08 | Cytori Therapeutics, Inc. | Methods of using regenerative cells to promote wound healing |
US8862202B2 (en) | 1998-09-14 | 2014-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8906107B2 (en) | 2001-05-25 | 2014-12-09 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
US8932363B2 (en) | 2002-11-07 | 2015-01-13 | Conformis, Inc. | Methods for determining meniscal size and shape and for devising treatment |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US8951259B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8998915B2 (en) | 2001-05-25 | 2015-04-07 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9020788B2 (en) | 1997-01-08 | 2015-04-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US9023050B2 (en) | 2001-05-25 | 2015-05-05 | Conformis, Inc. | Surgical tools for arthroplasty |
US9055953B2 (en) | 2001-05-25 | 2015-06-16 | Conformis, Inc. | Methods and compositions for articular repair |
US9066728B2 (en) | 2001-05-25 | 2015-06-30 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US9133431B2 (en) | 2009-05-01 | 2015-09-15 | Bimini Technologies Llc | Systems, methods and compositions for optimizing tissue and cell enriched grafts |
US9180015B2 (en) | 2008-03-05 | 2015-11-10 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
US9286686B2 (en) | 1998-09-14 | 2016-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
US9308053B2 (en) | 2006-02-06 | 2016-04-12 | Conformis, Inc. | Patient-specific joint arthroplasty devices for ligament repair |
US9308091B2 (en) | 2001-05-25 | 2016-04-12 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
US9326780B2 (en) | 2006-02-06 | 2016-05-03 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
US9387079B2 (en) | 2001-05-25 | 2016-07-12 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9480718B2 (en) | 2001-12-07 | 2016-11-01 | Cytori Therapeutics, Inc. | Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9486484B2 (en) | 2008-08-19 | 2016-11-08 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
US9495483B2 (en) | 2001-05-25 | 2016-11-15 | Conformis, Inc. | Automated Systems for manufacturing patient-specific orthopedic implants and instrumentation |
US9579110B2 (en) | 2001-05-25 | 2017-02-28 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9642632B2 (en) | 2009-02-24 | 2017-05-09 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US9649117B2 (en) | 2009-02-24 | 2017-05-16 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
US9700971B2 (en) | 2001-05-25 | 2017-07-11 | Conformis, Inc. | Implant device and method for manufacture |
US10085839B2 (en) | 2004-01-05 | 2018-10-02 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
Families Citing this family (243)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043234A1 (en) * | 1996-10-16 | 2005-02-24 | Deisher Theresa A. | Novel FGF homologs |
US20070233269A1 (en) * | 2001-05-25 | 2007-10-04 | Conformis, Inc. | Interpositional Joint Implant |
US20110071802A1 (en) * | 2009-02-25 | 2011-03-24 | Ray Bojarski | Patient-adapted and improved articular implants, designs and related guide tools |
US8735773B2 (en) | 2007-02-14 | 2014-05-27 | Conformis, Inc. | Implant device and method for manufacture |
US8771365B2 (en) * | 2009-02-25 | 2014-07-08 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs, and related tools |
US20090222103A1 (en) * | 2001-05-25 | 2009-09-03 | Conformis, Inc. | Articular Implants Providing Lower Adjacent Cartilage Wear |
US7618451B2 (en) * | 2001-05-25 | 2009-11-17 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools facilitating increased accuracy, speed and simplicity in performing total and partial joint arthroplasty |
US20110071645A1 (en) * | 2009-02-25 | 2011-03-24 | Ray Bojarski | Patient-adapted and improved articular implants, designs and related guide tools |
CN100529063C (en) * | 1997-12-02 | 2009-08-19 | 泽恩比奥公司 | Differentiation of adipose stromal cells into osteobalsts and uses thereof |
DE19755023C2 (en) * | 1997-12-11 | 2000-03-09 | Celanese Chem Europe Gmbh | Catalyst and process for making vinyl acetate |
US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
US7115417B1 (en) | 1998-05-01 | 2006-10-03 | Chancellor Michael B | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof |
US7001746B1 (en) | 1999-01-29 | 2006-02-21 | Artecel Sciences, Inc. | Methods and compositions for the differentiation of human preadipocytes into adipocytes |
US20050076396A1 (en) * | 1999-03-10 | 2005-04-07 | Katz Adam J. | Adipose-derived stem cells and lattices |
US20020095157A1 (en) * | 1999-07-23 | 2002-07-18 | Bowman Steven M. | Graft fixation device combination |
US6179840B1 (en) | 1999-07-23 | 2001-01-30 | Ethicon, Inc. | Graft fixation device and method |
US7078232B2 (en) * | 1999-08-19 | 2006-07-18 | Artecel, Inc. | Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof |
US6555374B1 (en) | 1999-08-19 | 2003-04-29 | Artecel Sciences, Inc. | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US6429013B1 (en) * | 1999-08-19 | 2002-08-06 | Artecel Science, Inc. | Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
US7687462B2 (en) * | 1999-10-05 | 2010-03-30 | The Regents Of The University Of California | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
WO2004024893A2 (en) * | 2002-09-13 | 2004-03-25 | The Regents Of The University Of California | Nell-1 enhanced bone mineralization |
US20090060988A1 (en) * | 1999-10-05 | 2009-03-05 | Kang Ting | Nell-1 enhanced bone mineralization |
US7884066B2 (en) * | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7052856B2 (en) * | 1999-10-05 | 2006-05-30 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
WO2006089023A2 (en) | 2005-02-16 | 2006-08-24 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
WO2001025402A1 (en) * | 1999-10-06 | 2001-04-12 | Tigenix N.V. | Isolation of precursor cells and their use for tissue repair |
DK1229940T3 (en) * | 1999-11-15 | 2014-08-18 | Piramal Healthcare Canada Ltd | TEMPERATURE CONTROL AND PH-DEPENDENT SELF-GELING, Aqueous BIOPOLYMER SOLUTION |
EP1237585B1 (en) * | 1999-12-09 | 2003-06-18 | Biosyntech Canada Inc. | Mineral-polymer hybrid composition |
US20030158302A1 (en) * | 1999-12-09 | 2003-08-21 | Cyric Chaput | Mineral-polymer hybrid composition |
US7582292B2 (en) | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
DE60132429T2 (en) * | 2000-02-26 | 2009-01-08 | Artecel, Inc. | PLURIPOTENTS FROM FAT-FROZEN-GENERIC STROMA CELLS GENERATED STRAIN CELLS AND THEIR USE |
WO2001078754A2 (en) * | 2000-04-14 | 2001-10-25 | University Of Pittsburgh | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof |
DE10026789B4 (en) * | 2000-05-31 | 2004-09-02 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Cartilage replacement and process for its manufacture |
EP1294414B1 (en) * | 2000-06-29 | 2006-03-15 | Biosyntech Canada Inc. | Composition and method for the repair and regeneration of cartilage and other tissues |
WO2002022014A1 (en) * | 2000-09-14 | 2002-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
US20020127265A1 (en) * | 2000-12-21 | 2002-09-12 | Bowman Steven M. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6599323B2 (en) * | 2000-12-21 | 2003-07-29 | Ethicon, Inc. | Reinforced tissue implants and methods of manufacture and use |
US6852330B2 (en) * | 2000-12-21 | 2005-02-08 | Depuy Mitek, Inc. | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
CA2365376C (en) * | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US7763769B2 (en) * | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US20030103947A1 (en) * | 2001-02-23 | 2003-06-05 | Urlich Noth | In vitro engineered cartilage constructs produced by coating biodegradable polymer with human mesenchymal stem cells |
US20030095952A1 (en) * | 2001-06-13 | 2003-05-22 | Krause Diane S. | Multi-organ engraftment with a single bone marrow-derived stem cell |
CN1636054A (en) * | 2001-07-06 | 2005-07-06 | 杰龙公司 | Mesenchymal cells and osteoblasts from human embryonic stem cell |
US20030054331A1 (en) * | 2001-09-14 | 2003-03-20 | Stemsource, Inc. | Preservation of non embryonic cells from non hematopoietic tissues |
JP2005506860A (en) | 2001-09-15 | 2005-03-10 | ラツシユ−プレスビテリアン−セント・リユークズ・メデイカル・センター | Layered cartilage tissue and engineering method thereof |
AU2002325758A1 (en) * | 2001-09-20 | 2003-04-01 | Centre For Translational Research In Cancer | Cultured stromal cells and uses thereof |
US20030165473A1 (en) * | 2001-11-09 | 2003-09-04 | Rush-Presbyterian-St. Luke's Medical Center | Engineered intervertebral disc tissue |
US8404229B2 (en) * | 2001-12-07 | 2013-03-26 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to treat acute tubular necrosis |
US20060204556A1 (en) * | 2001-12-07 | 2006-09-14 | Cytori Therapeutics, Inc. | Cell-loaded prostheses for regenerative intraluminal applications |
US7514075B2 (en) * | 2001-12-07 | 2009-04-07 | Cytori Therapeutics, Inc. | Systems and methods for separating and concentrating adipose derived stem cells from tissue |
US20050008626A1 (en) * | 2001-12-07 | 2005-01-13 | Fraser John K. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
WO2006075986A1 (en) * | 2005-01-10 | 2006-07-20 | Macropore Biosurgery, Inc. | Devices and methods for monitoring, managing, and servicing medical devices |
JP2005518828A (en) * | 2001-12-20 | 2005-06-30 | マクロポア インコーポレイテッド | System and method for treating a patient using a collagen-rich substance extracted from adipose tissue |
AU2003230792A1 (en) * | 2002-04-03 | 2003-10-20 | Artecel Sciences, Inc. | Improvements of adipocytic differentiated adipose derived adult stem cells and uses thereof |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7374678B2 (en) * | 2002-05-24 | 2008-05-20 | Biomet Biologics, Inc. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US20030205538A1 (en) * | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US20060278588A1 (en) * | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
AU2003249642A1 (en) * | 2002-05-24 | 2003-12-12 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
EP1513877B1 (en) | 2002-06-14 | 2008-01-16 | Cartela AB | Marker for stem cells and its use |
US20060127873A1 (en) * | 2002-07-16 | 2006-06-15 | Caroline Hoemann | Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
US7029006B2 (en) * | 2002-08-29 | 2006-04-18 | Canon Kabushiki Kaisha | Sheet feeding apparatus and image forming apparatus |
AR047712A1 (en) * | 2002-09-07 | 2006-02-15 | Royal Veterinary College | TREATMENT METHOD OF A NATURAL SOFT SKELETTIC TISSUE INJURY MANAGING A COMPOSITION OF MESENQUIMATOSE MOTHER CELLS |
JP2006501977A (en) | 2002-10-07 | 2006-01-19 | コンフォーミス・インコーポレイテッド | Minimally invasive joint implant with a three-dimensional profile that conforms to the joint surface |
JP4754823B2 (en) * | 2002-10-07 | 2011-08-24 | ザイモジェネティクス, インコーポレイテッド | Administration method of FGF18 |
US20040078090A1 (en) * | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US7824701B2 (en) * | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
JP2007524360A (en) * | 2003-02-07 | 2007-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | NELL peptide expression system and bone formation activity of NELL peptide |
US8197837B2 (en) | 2003-03-07 | 2012-06-12 | Depuy Mitek, Inc. | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
CN1812800B (en) * | 2003-04-25 | 2013-01-16 | 匹兹堡大学 | Muscle derived cells(mdc) for promoting and enhancing nerve repair and regeneration |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
US7875272B2 (en) | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
WO2005038012A2 (en) * | 2003-06-27 | 2005-04-28 | Ethicon Incorporated | Cartilage and bone repair and regeneration using postpartum-derived cells |
US8226715B2 (en) | 2003-06-30 | 2012-07-24 | Depuy Mitek, Inc. | Scaffold for connective tissue repair |
US20050020506A1 (en) * | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
US20050074877A1 (en) * | 2003-07-28 | 2005-04-07 | Mao Jeremy Jian | Biological engineering of articular structures containing both cartilage and bone |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
US20050202067A1 (en) * | 2003-10-28 | 2005-09-15 | Gkss Forschungszentrum | Matrix structure and hybrid matrix system for inducing a neofacia, their use and method for generating a neofacia |
US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US7901461B2 (en) * | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
WO2005072403A2 (en) | 2004-01-28 | 2005-08-11 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
US8193312B2 (en) | 2004-01-28 | 2012-06-05 | The Regents Of The University Of California | Bone morphogenic protein binding peptide |
US8415302B2 (en) | 2004-01-28 | 2013-04-09 | The Regents Of The University Of California | Surgical applications for BMP binding protein |
US11395865B2 (en) * | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
US7691607B2 (en) * | 2004-02-09 | 2010-04-06 | The Regents Of The University Of California | Expression system of NELL peptide |
US8221780B2 (en) * | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8657881B2 (en) * | 2004-04-20 | 2014-02-25 | Depuy Mitek, Llc | Meniscal repair scaffold |
US8137686B2 (en) * | 2004-04-20 | 2012-03-20 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
NL1026712C2 (en) * | 2004-07-23 | 2006-01-24 | Technologiestichting Stw | Bioresorbable bone implant. |
US20090029912A1 (en) | 2004-09-24 | 2009-01-29 | Stan Gronthos | Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc) |
WO2006032092A1 (en) | 2004-09-24 | 2006-03-30 | Angioblast Systems, Inc. | Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof |
WO2006050213A2 (en) * | 2004-10-29 | 2006-05-11 | Michalow Alexander E | Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway |
US7749250B2 (en) | 2006-02-03 | 2010-07-06 | Biomet Sports Medicine, Llc | Soft tissue repair assembly and associated method |
US8298262B2 (en) | 2006-02-03 | 2012-10-30 | Biomet Sports Medicine, Llc | Method for tissue fixation |
US8118836B2 (en) | 2004-11-05 | 2012-02-21 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US7658751B2 (en) | 2006-09-29 | 2010-02-09 | Biomet Sports Medicine, Llc | Method for implanting soft tissue |
US8088130B2 (en) | 2006-02-03 | 2012-01-03 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US9801708B2 (en) | 2004-11-05 | 2017-10-31 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US9017381B2 (en) | 2007-04-10 | 2015-04-28 | Biomet Sports Medicine, Llc | Adjustable knotless loops |
US8128658B2 (en) | 2004-11-05 | 2012-03-06 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to bone |
US7905904B2 (en) | 2006-02-03 | 2011-03-15 | Biomet Sports Medicine, Llc | Soft tissue repair device and associated methods |
US7909851B2 (en) | 2006-02-03 | 2011-03-22 | Biomet Sports Medicine, Llc | Soft tissue repair device and associated methods |
US8303604B2 (en) | 2004-11-05 | 2012-11-06 | Biomet Sports Medicine, Llc | Soft tissue repair device and method |
US8137382B2 (en) | 2004-11-05 | 2012-03-20 | Biomet Sports Medicine, Llc | Method and apparatus for coupling anatomical features |
US8361113B2 (en) | 2006-02-03 | 2013-01-29 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
JP2008540328A (en) * | 2004-11-29 | 2008-11-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Activated extraction of demineralized bone matrix |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
US20060171930A1 (en) * | 2004-12-21 | 2006-08-03 | Agnieszka Seyda | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
PL1831356T3 (en) | 2004-12-23 | 2017-07-31 | DePuy Synthes Products, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
CA2589063C (en) | 2004-12-23 | 2016-08-09 | Ethicon Incorporated | Treatment of parkinson's disease and related disorders using postpartum derived cells |
EP2399991B1 (en) | 2005-04-12 | 2017-09-27 | Mesoblast, Inc. | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
US8048297B2 (en) * | 2005-08-23 | 2011-11-01 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
CA2623834A1 (en) * | 2005-09-30 | 2007-04-12 | Conformis, Inc. | Joint arthroplasty devices |
WO2007051311A1 (en) * | 2005-11-04 | 2007-05-10 | Bio Syntech Canada Inc. | Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state |
WO2007070870A1 (en) * | 2005-12-16 | 2007-06-21 | Ethicon, Inc. | Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
EP1976975B1 (en) * | 2005-12-19 | 2012-08-01 | Ethicon, Inc. | In vitro expansion of postpartum derived cells in roller bottles |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
EP1979050B1 (en) * | 2005-12-28 | 2017-04-19 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using postpartum-derived cells |
CA2640185A1 (en) * | 2006-01-24 | 2007-08-02 | Christopher J. Centeno | Mesenchymal stem cell isolation and transplantation method and system to be used in a clinical setting |
JP2009525044A (en) * | 2006-01-30 | 2009-07-09 | ユニバーシティ オブ バージニア パテント ファウンデーション | Methods for preparing and characterizing mesenchymal stem cell aggregates and their use |
US8652171B2 (en) | 2006-02-03 | 2014-02-18 | Biomet Sports Medicine, Llc | Method and apparatus for soft tissue fixation |
US9538998B2 (en) | 2006-02-03 | 2017-01-10 | Biomet Sports Medicine, Llc | Method and apparatus for fracture fixation |
US11311287B2 (en) | 2006-02-03 | 2022-04-26 | Biomet Sports Medicine, Llc | Method for tissue fixation |
US8562647B2 (en) | 2006-09-29 | 2013-10-22 | Biomet Sports Medicine, Llc | Method and apparatus for securing soft tissue to bone |
US10517587B2 (en) | 2006-02-03 | 2019-12-31 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US9149267B2 (en) | 2006-02-03 | 2015-10-06 | Biomet Sports Medicine, Llc | Method and apparatus for coupling soft tissue to a bone |
US8562645B2 (en) | 2006-09-29 | 2013-10-22 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US8968364B2 (en) | 2006-02-03 | 2015-03-03 | Biomet Sports Medicine, Llc | Method and apparatus for fixation of an ACL graft |
US9468433B2 (en) | 2006-02-03 | 2016-10-18 | Biomet Sports Medicine, Llc | Method and apparatus for forming a self-locking adjustable loop |
US9078644B2 (en) | 2006-09-29 | 2015-07-14 | Biomet Sports Medicine, Llc | Fracture fixation device |
US11259792B2 (en) | 2006-02-03 | 2022-03-01 | Biomet Sports Medicine, Llc | Method and apparatus for coupling anatomical features |
US8801783B2 (en) | 2006-09-29 | 2014-08-12 | Biomet Sports Medicine, Llc | Prosthetic ligament system for knee joint |
US8597327B2 (en) | 2006-02-03 | 2013-12-03 | Biomet Manufacturing, Llc | Method and apparatus for sternal closure |
US7838022B2 (en) | 2006-05-01 | 2010-11-23 | Warsaw Orthopedic, Inc | Malleable implants containing demineralized bone matrix |
US8506983B2 (en) * | 2006-05-01 | 2013-08-13 | Warsaw Orthopedic, Inc. | Bone filler material |
US20100209470A1 (en) * | 2006-05-01 | 2010-08-19 | Warsaw Orthopedic, Inc. An Indiana Corporation | Demineralized bone matrix devices |
US7771741B2 (en) * | 2006-05-01 | 2010-08-10 | Warsaw Orthopedic, Inc | Demineralized bone matrix devices |
US20070264238A1 (en) * | 2006-05-09 | 2007-11-15 | Shaw Robert A | Procedure to regenerate articular cartilage in human advanced osteoarthritis using autologous hematopoetic stem cell transplantation |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8430813B2 (en) * | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
WO2007139551A1 (en) * | 2006-05-30 | 2007-12-06 | Cytori Therapeutics, Inc. | Systems and methods for manipulation of regenerative cells from adipose tissue |
US20100015104A1 (en) * | 2006-07-26 | 2010-01-21 | Cytori Therapeutics, Inc | Generation of adipose tissue and adipocytes |
US20080033572A1 (en) * | 2006-08-03 | 2008-02-07 | Ebi L.P. | Bone graft composites and methods of treating bone defects |
US11259794B2 (en) | 2006-09-29 | 2022-03-01 | Biomet Sports Medicine, Llc | Method for implanting soft tissue |
US8672969B2 (en) | 2006-09-29 | 2014-03-18 | Biomet Sports Medicine, Llc | Fracture fixation device |
EP2076275B1 (en) * | 2006-10-06 | 2014-12-03 | University Of Virginia Patent Foundation | Compositions useful for diabetic wound healing |
WO2008100442A1 (en) * | 2007-02-09 | 2008-08-21 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
US8034014B2 (en) * | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
US7632340B2 (en) * | 2007-03-07 | 2009-12-15 | Hamilton Beach Brands, Inc. | Air purifier for removing particles or contaminants from air |
US8283169B1 (en) | 2007-03-21 | 2012-10-09 | Allan Yang Wu | Differential gradient separation of cells |
EP2146794B1 (en) | 2007-04-12 | 2016-10-19 | Biomet Biologics, LLC | Buoy suspension fractionation system |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
US8137354B2 (en) | 2007-04-25 | 2012-03-20 | Biomet Sports Medicine, Llc | Localized cartilage defect therapy |
US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
US20130261606A1 (en) * | 2007-04-30 | 2013-10-03 | Andrew Technologies Llc | Harvesting Fat Tissue Using Tissue Liquefaction |
US9095562B2 (en) * | 2007-07-05 | 2015-08-04 | Regenerative Sciences, Inc. | Methods and compositions for optimized expansion and implantation of mesenchymal stem cells |
UA99152C2 (en) * | 2007-10-05 | 2012-07-25 | Этикон, Инкорпорейтед | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US9295564B2 (en) * | 2007-10-19 | 2016-03-29 | Spinesmith Partners, L.P. | Fusion methods using autologous stem cells |
US20090105824A1 (en) * | 2007-10-19 | 2009-04-23 | Jones Robert J | Spinal fusion device and associated methods |
US9056150B2 (en) | 2007-12-04 | 2015-06-16 | Warsaw Orthopedic, Inc. | Compositions for treating bone defects |
US20110200642A1 (en) * | 2007-12-19 | 2011-08-18 | Regenerative Sciences, Llc | Compositions and Methods to Promote Implantation and Engrafment of Stem Cells |
US8236538B2 (en) * | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
US20090192528A1 (en) * | 2008-01-29 | 2009-07-30 | Biomet Biologics, Inc. | Method and device for hernia repair |
WO2009108890A1 (en) | 2008-02-27 | 2009-09-03 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
WO2009111338A1 (en) * | 2008-02-29 | 2009-09-11 | Biomet Manufacturing Corp. | A system and process for separating a material |
AU2009221773B2 (en) * | 2008-03-05 | 2015-03-05 | Conformis, Inc. | Edge-matched articular implant |
CN102026546A (en) | 2008-03-14 | 2011-04-20 | 再生科学有限责任公司 | Compositions and methods for cartilage repair |
US8840913B2 (en) | 2008-03-27 | 2014-09-23 | Warsaw Orthopedic, Inc. | Malleable multi-component implants and materials therefor |
EP2274023B1 (en) | 2008-04-10 | 2019-12-11 | Bonus Therapeutics Ltd | Bone-like prosthetic implants |
US20100098739A1 (en) * | 2008-10-20 | 2010-04-22 | University Of Virginia Patent Foundation | Compositions and methods for modular soft tissue repair |
US9192695B2 (en) * | 2008-11-20 | 2015-11-24 | Allosource | Allografts combined with tissue derived stem cells for bone healing |
KR20120006481A (en) | 2008-12-05 | 2012-01-18 | 리제너러티브 사이언시즈, 엘엘씨 | Methods and compositions to facilitate repair of avascular tissue |
US20100168022A1 (en) * | 2008-12-11 | 2010-07-01 | Centeno Christopher J | Use of In-Vitro Culture to Design or Test Personalized Treatment Regimens |
PL2379088T3 (en) | 2008-12-19 | 2018-07-31 | DePuy Synthes Products, Inc. | Treatment of lung and pulmonary diseases and disorders |
US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
BRPI0923070A2 (en) * | 2008-12-19 | 2016-06-14 | Atrm Llc | "Uses of compositions for regeneration and repair of neural tissue after injury, said compositions, and kit" |
SI2379087T1 (en) * | 2008-12-19 | 2015-01-30 | DePuy Synthes Products, LLC | Umbilical cord tissue derived cells for treating neuropathic pain and spasticity |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
AU2010229651B2 (en) * | 2009-03-26 | 2014-05-08 | Advanced Technologies And Regenerative Medicine, Llc | Human umbilical cord tissue cells as therapy for Alzheimer' s disease |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
WO2011005298A2 (en) | 2009-06-23 | 2011-01-13 | The Regents Of The University Of California | Enhancement of bmp retention |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US20110054929A1 (en) * | 2009-09-01 | 2011-03-03 | Cell Solutions Colorado Llc | Stem Cell Marketplace |
US9113950B2 (en) | 2009-11-04 | 2015-08-25 | Regenerative Sciences, Llc | Therapeutic delivery device |
US20140286911A1 (en) | 2013-03-15 | 2014-09-25 | Allosource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
JP4995888B2 (en) * | 2009-12-15 | 2012-08-08 | 株式会社神戸製鋼所 | Stainless steel arc welding flux cored wire |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US9260697B2 (en) | 2010-07-09 | 2016-02-16 | The Gid Group, Inc. | Apparatus and methods relating to collecting and processing human biological material containing adipose |
US9296984B2 (en) | 2010-07-09 | 2016-03-29 | The Gid Group, Inc. | Tissue processing apparatus and method for processing adipose tissue |
WO2013106655A1 (en) | 2012-01-11 | 2013-07-18 | The Gid Group, Inc. | Method for processing adipose tissue and processing apparatus |
US9206387B2 (en) | 2010-07-09 | 2015-12-08 | The Gid Group, Inc. | Method and apparatus for processing adipose tissue |
EP2625264B1 (en) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
CA2818657C (en) | 2010-11-25 | 2016-01-05 | Kuraray Co., Ltd. | Method for producing implant material |
WO2012154301A1 (en) | 2011-03-18 | 2012-11-15 | Tornier, Inc. | Allogeneic microvascular tissue for soft tissue treatments |
JP2014518670A (en) * | 2011-04-29 | 2014-08-07 | アンドリュー・テクノロジーズ・エルエルシー | Collection of adipose tissue using tissue liquefaction |
ES2803499T3 (en) | 2011-06-29 | 2021-01-27 | Biorestorative Therapies Inc | Brown Fat Cell Compositions and Methods |
US9357991B2 (en) | 2011-11-03 | 2016-06-07 | Biomet Sports Medicine, Llc | Method and apparatus for stitching tendons |
US9314241B2 (en) | 2011-11-10 | 2016-04-19 | Biomet Sports Medicine, Llc | Apparatus for coupling soft tissue to a bone |
US9381013B2 (en) | 2011-11-10 | 2016-07-05 | Biomet Sports Medicine, Llc | Method for coupling soft tissue to a bone |
KR101981450B1 (en) | 2011-12-23 | 2019-08-28 | 디퍼이 신테스 프로덕츠, 인코포레이티드 | Detection of human umbilical cord tissue-derived cells |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
EP3075841B1 (en) | 2012-09-06 | 2021-03-10 | GID BIO, Inc. | Tissue processing apparatus and method for processing adipose tissue |
DK2898064T3 (en) | 2012-09-19 | 2019-03-04 | Microvascular Tissues Inc | COMPOSITIONS FOR TREATMENT AND PREVENTION OF TISSUE DAMAGE AND DISEASE |
US11819522B2 (en) | 2012-09-19 | 2023-11-21 | Microvascular Tissues, Inc. | Compositions and methods for treating and preventing tissue injury and disease |
US10596202B2 (en) | 2012-09-19 | 2020-03-24 | Microvascular Tissues, Inc. | Compositions and methods for treating and preventing tissue injury and disease |
US9872937B2 (en) | 2012-09-19 | 2018-01-23 | Microvascular Tissues, Inc. | Compositions and methods for treating and preventing tissue injury and disease |
US9918827B2 (en) | 2013-03-14 | 2018-03-20 | Biomet Sports Medicine, Llc | Scaffold for spring ligament repair |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
EP3038629B1 (en) | 2013-09-05 | 2020-11-18 | GID BIO, Inc. | Method for processing adipose tissue |
WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
US11433163B2 (en) | 2014-04-10 | 2022-09-06 | Bonus Therapeutics Ltd. | Bone repair compositions |
EP3137139A1 (en) | 2014-05-02 | 2017-03-08 | Lifecell Corporation | Injection sensor with feedback mechanism |
US10918669B2 (en) | 2014-07-25 | 2021-02-16 | Recellerate, Inc. | Methods of treating exercise-induced pulmonary hemorrhage |
US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
JP6801993B2 (en) * | 2015-10-05 | 2020-12-16 | 株式会社 ジャパン・ティッシュ・エンジニアリング | Chondrocyte injection kit |
BR112018008059A2 (en) | 2015-10-21 | 2018-10-23 | Lifecell Corp | medical device control systems and methods |
CA3002078A1 (en) | 2015-10-21 | 2017-04-27 | Lifecell Corporation | Systems and methods for tube management |
CA3008035A1 (en) | 2015-12-22 | 2017-06-29 | Lifecell Corporation | Syringe filling device for fat transfer |
EP3464565A4 (en) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
JP2019526342A (en) | 2016-08-30 | 2019-09-19 | ライフセル コーポレーションLifeCell Corporation | System and method for controlling medical devices |
USD851777S1 (en) | 2017-01-30 | 2019-06-18 | Lifecell Corporation | Canister-type device for tissue processing |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
WO2019018002A1 (en) | 2017-07-18 | 2019-01-24 | The Gid Group, Inc. | Adipose tissue digestion system and tissue processing method |
CN108379663B (en) * | 2018-04-24 | 2023-05-26 | 中国人民解放军第四军医大学 | Device and method for trapping and enriching cells in porous regular body scaffold material |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5716616A (en) * | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4609551A (en) | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
US5230693A (en) | 1985-06-06 | 1993-07-27 | Thomas Jefferson University | Implantable prosthetic device for implantation into a human patient having a surface treated with microvascular endothelial cells |
US4820626A (en) | 1985-06-06 | 1989-04-11 | Thomas Jefferson University | Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surface itself |
GB8803697D0 (en) | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
JP2820415B2 (en) | 1988-03-14 | 1998-11-05 | ティーエイチエム・バイオメディカル・インコーポレイテッド | Biodegradable and osteogenic graft bone graft substitute composition |
US5081030A (en) * | 1989-04-25 | 1992-01-14 | The Johns Hopkins University | Release of cells from affinity matrices |
WO1991001720A1 (en) | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
US5197985A (en) | 1990-11-16 | 1993-03-30 | Caplan Arnold I | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells |
EP1361267A3 (en) | 1991-06-18 | 2003-11-26 | CAPLAN, Arnold I. | Mesenchymal stem cells and their use |
US5672346A (en) * | 1992-07-27 | 1997-09-30 | Indiana University Foundation | Human stem cell compositions and methods |
US5411885A (en) | 1993-12-17 | 1995-05-02 | New York Blood Center, Inc. | Methods for tissue embedding and tissue culturing |
WO1996001641A1 (en) * | 1994-07-08 | 1996-01-25 | Sulzer Medizinaltechnik Ag | Method of manufacturing implant materials |
EP0877795A4 (en) * | 1996-01-16 | 2003-03-05 | Depuy Orthopaedics Inc | Isolation of precursor cells from hematopoietic and non-hematopoietic tissues and their use |
-
1997
- 1997-07-14 US US08/891,952 patent/US6200606B1/en not_active Expired - Fee Related
-
1998
- 1998-07-14 JP JP2000502153A patent/JP2003517259A/en active Pending
- 1998-07-14 AU AU84040/98A patent/AU756411B2/en not_active Ceased
- 1998-07-14 EP EP98934544A patent/EP1007632A4/en not_active Withdrawn
- 1998-07-14 WO PCT/US1998/014587 patent/WO1999002654A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5226914A (en) * | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5716616A (en) * | 1995-03-28 | 1998-02-10 | Thomas Jefferson University | Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects |
Non-Patent Citations (2)
Title |
---|
See also references of EP1007632A4 * |
SIMMONS P. J., TOROK-STORB B.: "CD34 EXPRESSION BY STROMAL PRECURSORS IN NORMAL HUMAN ADULT BONE MARROW.", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 78., no. 11., 1 December 1991 (1991-12-01), US, pages 2848 - 2853., XP002914847, ISSN: 0006-4971 * |
Cited By (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9020788B2 (en) | 1997-01-08 | 2015-04-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9286686B2 (en) | 1998-09-14 | 2016-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and assessing cartilage loss |
USRE43282E1 (en) | 1998-09-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and devising treatment |
US8862202B2 (en) | 1998-09-14 | 2014-10-14 | The Board Of Trustees Of The Leland Stanford Junior University | Assessing the condition of a joint and preventing damage |
US6777231B1 (en) | 1999-03-10 | 2004-08-17 | The Regents Of The University Of California | Adipose-derived stem cells and lattices |
EP1165830A4 (en) * | 1999-03-10 | 2003-10-08 | Univ Pittsburgh | Adipose-derived stem cells and lattices |
US7470537B2 (en) | 1999-03-10 | 2008-12-30 | Univ California | Adipose-derived stem cells and lattices |
JP2015109834A (en) * | 1999-03-10 | 2015-06-18 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | Adipose-derived stem cells and lattices |
JP2002537849A (en) * | 1999-03-10 | 2002-11-12 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | Fat-derived stem cells and lattice |
JP2011078416A (en) * | 1999-03-10 | 2011-04-21 | Univ Of Pittsburgh Of The Commonwealth System Of Higher Education | Adipose-derived stem cells and lattices |
WO2001080865A2 (en) * | 2000-04-25 | 2001-11-01 | Osiris Therapeutics, Inc. | Joint repair using mesenchymal stem cells |
AU2006200478B2 (en) * | 2000-04-25 | 2007-08-02 | Mesoblast International Sarl | Joint repair using mesenchymal stem cells |
WO2001080865A3 (en) * | 2000-04-25 | 2002-04-11 | Osiris Therapeutics Inc | Joint repair using mesenchymal stem cells |
WO2002055678A1 (en) * | 2001-01-10 | 2002-07-18 | Centre National De La Recherche Scientifique-Cnrs | Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues |
US9125672B2 (en) | 2001-05-25 | 2015-09-08 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9055953B2 (en) | 2001-05-25 | 2015-06-16 | Conformis, Inc. | Methods and compositions for articular repair |
US9439767B2 (en) | 2001-05-25 | 2016-09-13 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9387079B2 (en) | 2001-05-25 | 2016-07-12 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9358018B2 (en) | 2001-05-25 | 2016-06-07 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9333085B2 (en) | 2001-05-25 | 2016-05-10 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US9495483B2 (en) | 2001-05-25 | 2016-11-15 | Conformis, Inc. | Automated Systems for manufacturing patient-specific orthopedic implants and instrumentation |
US9308091B2 (en) | 2001-05-25 | 2016-04-12 | Conformis, Inc. | Devices and methods for treatment of facet and other joints |
US9295482B2 (en) | 2001-05-25 | 2016-03-29 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9579110B2 (en) | 2001-05-25 | 2017-02-28 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9216025B2 (en) | 2001-05-25 | 2015-12-22 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9186254B2 (en) | 2001-05-25 | 2015-11-17 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US9186161B2 (en) | 2001-05-25 | 2015-11-17 | Conformis, Inc. | Surgical tools for arthroplasty |
US9603711B2 (en) | 2001-05-25 | 2017-03-28 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9125673B2 (en) | 2001-05-25 | 2015-09-08 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US8545569B2 (en) | 2001-05-25 | 2013-10-01 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US9700971B2 (en) | 2001-05-25 | 2017-07-11 | Conformis, Inc. | Implant device and method for manufacture |
US8690945B2 (en) | 2001-05-25 | 2014-04-08 | Conformis, Inc. | Patient selectable knee arthroplasty devices |
US9877790B2 (en) | 2001-05-25 | 2018-01-30 | Conformis, Inc. | Tibial implant and systems with variable slope |
US9107679B2 (en) | 2001-05-25 | 2015-08-18 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8906107B2 (en) | 2001-05-25 | 2014-12-09 | Conformis, Inc. | Patient-adapted and improved orthopedic implants, designs and related tools |
US8926706B2 (en) | 2001-05-25 | 2015-01-06 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9107680B2 (en) | 2001-05-25 | 2015-08-18 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8945230B2 (en) | 2001-05-25 | 2015-02-03 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
US8951260B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Surgical cutting guide |
US8951259B2 (en) | 2001-05-25 | 2015-02-10 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9775680B2 (en) | 2001-05-25 | 2017-10-03 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US8974539B2 (en) | 2001-05-25 | 2015-03-10 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US9084617B2 (en) | 2001-05-25 | 2015-07-21 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US8998915B2 (en) | 2001-05-25 | 2015-04-07 | Conformis, Inc. | Joint arthroplasty devices and surgical tools |
US9072531B2 (en) | 2001-05-25 | 2015-07-07 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9066728B2 (en) | 2001-05-25 | 2015-06-30 | Conformis, Inc. | Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty |
US9023050B2 (en) | 2001-05-25 | 2015-05-05 | Conformis, Inc. | Surgical tools for arthroplasty |
EP1434855A4 (en) * | 2001-09-10 | 2006-03-29 | Univ California | Adipose-derived stem cells and lattices |
EP1434855A2 (en) * | 2001-09-10 | 2004-07-07 | The Regents of the University of California | Adipose-derived stem cells and lattices |
US9511096B2 (en) | 2001-12-07 | 2016-12-06 | Cytori Therapeutics, Inc. | Methods of using regenerative cells to treat an ischemic wound |
US7595043B2 (en) | 2001-12-07 | 2009-09-29 | Cytori Therapeutics, Inc. | Method for processing and using adipose-derived stem cells |
US9480718B2 (en) | 2001-12-07 | 2016-11-01 | Cytori Therapeutics, Inc. | Methods of using adipose-derived regenerative cells in the treatment of peripheral vascular disease and related disorders |
US9463203B2 (en) | 2001-12-07 | 2016-10-11 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of cartilage defects |
US7429488B2 (en) | 2001-12-07 | 2008-09-30 | Cytori Therapeutics, Inc. | Method for processing lipoaspirate cells |
US8883499B2 (en) | 2001-12-07 | 2014-11-11 | Cytori Therapeutics, Inc. | Systems and methods for isolating and using clinically safe adipose derived regenerative cells |
US8691216B2 (en) | 2001-12-07 | 2014-04-08 | Cytori Therapeutics, Inc. | Methods of using regenerative cells to promote wound healing |
US9872877B2 (en) | 2001-12-07 | 2018-01-23 | Cytori Therapeutics, Inc. | Methods of using regenerative cells to promote epithelialization or neodermis formation |
US7390484B2 (en) | 2001-12-07 | 2008-06-24 | Cytori Therapeutics, Inc. | Self-contained adipose derived stem cell processing unit |
EP2305276A3 (en) * | 2001-12-07 | 2011-09-21 | Cytori Therapeutics, Inc. | Processed lipoaspirate cells for use in therapy |
US9597395B2 (en) | 2001-12-07 | 2017-03-21 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions |
US7771716B2 (en) | 2001-12-07 | 2010-08-10 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of musculoskeletal disorders |
US7473420B2 (en) | 2001-12-07 | 2009-01-06 | Cytori Therapeutics, Inc. | Systems and methods for treating patients with processed lipoaspirate cells |
US9198937B2 (en) | 2001-12-07 | 2015-12-01 | Cytori Therapeutics, Inc. | Adipose-derived regenerative cells for treating liver injury |
US7501115B2 (en) | 2001-12-07 | 2009-03-10 | Cytori Therapeutics, Inc. | Systems and methods for treating patients with processed lipoaspirate cells |
US7585670B2 (en) | 2001-12-07 | 2009-09-08 | Cytori Therapeutics, Inc. | Automated methods for isolating and using clinically safe adipose derived regenerative cells |
US9504716B2 (en) | 2001-12-07 | 2016-11-29 | Cytori Therapeutics, Inc. | Methods of using adipose derived regenerative cells to promote restoration of intevertebral disc |
US9849149B2 (en) | 2001-12-07 | 2017-12-26 | Cytori Therapeutics, Inc. | Methods of using regenerative cells in the treatment of erectile dysfunction |
US7687059B2 (en) | 2001-12-07 | 2010-03-30 | Cytori Therapeutics, Inc. | Systems and methods for treating patients with processed lipoaspirate cells |
US9492483B2 (en) | 2001-12-07 | 2016-11-15 | Cytori Therapeutics, Inc. | Methods of using regenerative cells to treat a burn |
US7651684B2 (en) | 2001-12-07 | 2010-01-26 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in augmenting autologous fat transfer |
US8932363B2 (en) | 2002-11-07 | 2015-01-13 | Conformis, Inc. | Methods for determining meniscal size and shape and for devising treatment |
US8965088B2 (en) | 2002-11-07 | 2015-02-24 | Conformis, Inc. | Methods for determining meniscal size and shape and for devising treatment |
US10085839B2 (en) | 2004-01-05 | 2018-10-02 | Conformis, Inc. | Patient-specific and patient-engineered orthopedic implants |
US8986744B2 (en) | 2004-02-11 | 2015-03-24 | Aldagen, Inc. | Stem cell populations and methods of use |
US7863043B2 (en) | 2004-02-11 | 2011-01-04 | Aldagen, Inc. | Stem cell populations and methods of use |
US7531355B2 (en) | 2005-07-29 | 2009-05-12 | The Regents Of The University Of California | Methods and compositions for smooth muscle reconstruction |
EP1915109A4 (en) * | 2005-08-01 | 2011-05-18 | Univ Louisiana State | Use of adipose tissue-derived stromal cells in spinal fusion |
EP1915109A2 (en) * | 2005-08-01 | 2008-04-30 | Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Use of adipose tissue-derived stromal cells in spinal fusion |
US9220516B2 (en) | 2006-02-06 | 2015-12-29 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US9326780B2 (en) | 2006-02-06 | 2016-05-03 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools incorporating anatomical relief |
US9308053B2 (en) | 2006-02-06 | 2016-04-12 | Conformis, Inc. | Patient-specific joint arthroplasty devices for ligament repair |
US9220517B2 (en) | 2006-02-06 | 2015-12-29 | Conformis, Inc. | Patient selectable joint arthroplasty devices and surgical tools |
US7416889B2 (en) | 2006-04-27 | 2008-08-26 | Rhode Island Hospital | Methods and compositions for repairing cartilage |
WO2007127436A3 (en) * | 2006-04-27 | 2008-06-05 | Rhode Island Hospital | Methods and compositions for repairing cartilage |
WO2007127436A2 (en) * | 2006-04-27 | 2007-11-08 | Rhode Island Hospital | Methods and compositions for repairing cartilage |
US9700420B2 (en) | 2008-03-05 | 2017-07-11 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
US9180015B2 (en) | 2008-03-05 | 2015-11-10 | Conformis, Inc. | Implants for altering wear patterns of articular surfaces |
US9486484B2 (en) | 2008-08-19 | 2016-11-08 | Cytori Therapeutics, Inc. | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease |
US10512476B2 (en) | 2009-02-24 | 2019-12-24 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US11154305B2 (en) | 2009-02-24 | 2021-10-26 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US11911046B2 (en) | 2009-02-24 | 2024-02-27 | Microport Orthopedics Holdings, Inc. | Patient specific surgical guide locator and mount |
US9675365B2 (en) | 2009-02-24 | 2017-06-13 | Microport Orthopedics Holdings Inc. | System and method for anterior approach for installing tibial stem |
US9113914B2 (en) | 2009-02-24 | 2015-08-25 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US9642632B2 (en) | 2009-02-24 | 2017-05-09 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US9089342B2 (en) | 2009-02-24 | 2015-07-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US11779356B2 (en) | 2009-02-24 | 2023-10-10 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9017334B2 (en) | 2009-02-24 | 2015-04-28 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US9566075B2 (en) | 2009-02-24 | 2017-02-14 | Microport Orthopedics Holdings Inc. | Patient specific surgical guide locator and mount |
US9883870B2 (en) | 2009-02-24 | 2018-02-06 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US9901353B2 (en) | 2009-02-24 | 2018-02-27 | Microport Holdings Inc. | Patient specific surgical guide locator and mount |
US9949747B2 (en) | 2009-02-24 | 2018-04-24 | Microport Orthopedics Holdings, Inc. | Systems and methods for installing an orthopedic implant |
US10039557B2 (en) | 2009-02-24 | 2018-08-07 | Micorport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9320620B2 (en) | 2009-02-24 | 2016-04-26 | Conformis, Inc. | Patient-adapted and improved articular implants, designs and related guide tools |
US11779347B2 (en) | 2009-02-24 | 2023-10-10 | Microport Orthopedics Holdings Inc. | System for forming a patient specific surgical guide mount |
US10646238B2 (en) | 2009-02-24 | 2020-05-12 | Microport Orthopedics Holdings, Inc. | Systems and methods for installing an orthopedic implant |
US10660654B2 (en) | 2009-02-24 | 2020-05-26 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US10973536B2 (en) | 2009-02-24 | 2021-04-13 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US9649117B2 (en) | 2009-02-24 | 2017-05-16 | Microport Orthopedics Holdings, Inc. | Orthopedic surgical guide |
US11389177B2 (en) | 2009-02-24 | 2022-07-19 | Microport Orthopedics Holdings Inc. | Method for forming a patient specific surgical guide mount |
US11464527B2 (en) | 2009-02-24 | 2022-10-11 | Microport Orthopedics Holdings Inc. | Systems and methods for installing an orthopedic implant |
US11534186B2 (en) | 2009-02-24 | 2022-12-27 | Microport Orthopedics Holdings Inc. | Orthopedic surgical guide |
US9133431B2 (en) | 2009-05-01 | 2015-09-15 | Bimini Technologies Llc | Systems, methods and compositions for optimizing tissue and cell enriched grafts |
US9486226B2 (en) | 2012-04-18 | 2016-11-08 | Conformis, Inc. | Tibial guides, tools, and techniques for resecting the tibial plateau |
US9675471B2 (en) | 2012-06-11 | 2017-06-13 | Conformis, Inc. | Devices, techniques and methods for assessing joint spacing, balancing soft tissues and obtaining desired kinematics for joint implant components |
Also Published As
Publication number | Publication date |
---|---|
AU756411B2 (en) | 2003-01-09 |
AU8404098A (en) | 1999-02-08 |
JP2003517259A (en) | 2003-05-27 |
US6200606B1 (en) | 2001-03-13 |
EP1007632A4 (en) | 2003-09-10 |
EP1007632A1 (en) | 2000-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6200606B1 (en) | Isolation of precursor cells from hematopoietic and nonhematopoietic tissues and their use in vivo bone and cartilage regeneration | |
WO1997026326A1 (en) | Isolation of precursor cells from hematopoietic and non-hematopoietic tissues and their use | |
KR101704072B1 (en) | Allografts combined with tissue derived stem cells for bone healing | |
Kadiyala et al. | Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro | |
CA2583151C (en) | Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue | |
Kramer et al. | In vivo matrix-guided human mesenchymal stem cells | |
US5965436A (en) | Method of isolating mesenchymal stem cells associated with isolated megakaryocytes by isolating megakaryocytes | |
US5197985A (en) | Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells | |
US5908784A (en) | In vitro chondrogenic induction of human mesenchymal stem cells | |
WO1998020731A9 (en) | Msc-megakaryocyte precursor composition and method of isolating mscs associated with isolated megakaryocytes by isolating megakaryocytes | |
JP2005517441A (en) | Method for separating and culturing mesenchymal stem cells / progenitor cells derived from cord blood and method for inducing differentiation into mesenchymal tissue | |
US20160067377A1 (en) | Stem Cell Seeded Natural Substrates and Methods Relating Thereto | |
AU2011253985B2 (en) | Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 84040/98 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998934544 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998934544 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 84040/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998934544 Country of ref document: EP |